Day: 2025-03-28

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 飛魚科技國際有限公司（「飛魚科技」或「公司」或「集團」，股份代號：1022.HK）董事會欣然宣佈本集團截至2024年12月31日止年度的綜合年度業績。截止2024年12月31日止年度，飛魚科技收益總額約人民幣276.7百萬元，同比增長22.4%。其中，遊戲營運收益約為人民幣238.8百萬元，較2023年度約人民幣174.7百萬元增加約36.7%，該增長主要由於在2024年8月1日推出廣受用戶歡迎的「一步兩步」。2024年，中國線上遊戲行業複甦趨勢顯著，而其中HTML5遊戲表現尤為突出，收益同比增長近100%至人民幣398億元。飛魚科技緊抓機遇，於2024年成功推出以HTML5遊戲為主的三款新遊戲，其中「一步兩步」憑藉獨特玩法與高質量體驗，贏得玩家高度認可，並於2025年1月在微信小遊戲暢銷榜攀升至第八位。該遊戲在營运收益與廣告收益方面貢獻顯著，已成為驅動公司收益增長的核心動力。未來，飛魚科技將繼續於HTML5、手機應用程式及主機等多個平台開發新遊戲，並且將充分發揮自身優勢，持續投資「一步兩步」，進一步挖掘其市場潛力。同時，公司計劃於2025年上線主機遊戲「霓虹深淵2」，拓展多平台佈局，以滿足不同玩家群體的需求。值得關注的是，在積極投資推出新遊戲的同時，公司長期運營的經典遊戲「神仙道」、「三國之刃」及「保衛蘿蔔」系列也仍持續提供穩定現金流。其中，「保衛蘿蔔4」廣告收益同比增長22.2%，用戶黏性穩固且持續吸引廣告主，體現了公司培育及維持既有知識產權的能力，這也彰顯了公司的知識產權於激烈的市場競爭中仍保持強勁的盈利能力。此外，公司還積極擴展知識產權邊界，推出以「蘿蔔阿波」為原型的收藏模型，2024年，該系列新增6個產品系列，部分限量模型發售5分鐘即售罄。為進一步強化知識產權與粉絲之間的情感連結，提升知識產權商業價值，飛魚科技還通過展覽、快閃活動及文化沙龍等各種線下渠道，提高相關知識產權的實際曝光率。這種線下活動一方面可以深化與現有粉絲的互動，另一方面也可以吸引更多新客戶，在一定程度上展現了公司於在線遊戲之外的創新及價值創造能力，有助於進一步鞏固公司的品牌影響力和市場佔有率。展望未來，飛魚科技表示，儘管行業或將面臨競爭激烈、客戶獲取成本上漲及消費者信心減弱等挑戰，但公司有信心憑藉在創造具吸引力且富文化底蘊的遊戲體驗方面的專業知識把握機遇。此外，公司還計劃挖掘海外市場機遇，將旗下遊戲推向更廣泛的全球受眾，豐富收益來源，為玩家與股東提供持續價值。關於飛魚科技國際有限公司飛魚科技是國內領先互聯網遊戲開發和運營商，本著"用簡單創造精彩"的企業理念，致力於互動娛樂產品的研發與運營。2014年12月，飛魚科技成功登陸香港聯交所上市（01022.HK），為廈門地區首家在香港上市的遊戲公司。飛魚科技在全國進行戰略化佈局，分支機構遍佈北京、深圳等國內主要城市；集團旗下擁有數款精品網路遊戲產品，如《神仙道》、《保衛蘿蔔》系列、《三國之刃》、《超級幻影貓》系列等，並在多個細分領域開展專業化佈局，陸續推出了《英雄就是我》、《初體計劃》、《你胖你先吃》等多款精品獨立遊戲及輕度休閒遊戲。憑藉優質的產品、服務品質、受歡迎程度獲得多項行業重要獎項及玩家認可，累計遊戲用戶數超過十億，遍及中國大陸及海外地區。如欲瞭解更多關於飛魚科技，請瀏覽https://www.feiyu.com/。如有垂詢，請聯絡慧悅公共關係顧問集團有限公司：Anne Lin / Ken Wu / Jane Zhuang電話：(86) 13556417482 / (86) 15607493246 / (86)13537575478電郵：anne.lin@intelligentjoy.com / ken.wu@intelligentjoy.com / jane.zhuang@intelligentjoy.com Copyright 2025 亞太商訊 via SeaPRwire.com.

深圳, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 由深圳市殘聯和龍華區人民政府指導，區殘工委主辦、區殘聯承辦的"孤獨星球-星光跑"公益活動將於3月30日上午在深圳龍華人才綠道群賢廣場正式開跑。本次活動旨在提升社會對自閉症群體的認知，推動社會各界共同為他們構建更加友好的成長環境。作為本次活動的主要協辦單位，深圳海納特教集團正積極籌備，號召自閉症兒童及家長、特教從業者和社會各界愛心人士踴躍參與。孤獨症，又稱自閉症，是一種廣泛性發育障礙，主要表現為社交障礙、語言溝通困難和刻板行為模式。世界衛生組織（WHO）資料顯示，全球每100名兒童中就有1名被診斷為孤獨症。為提高公眾對這一群體的關注度，聯合國自2008年起將每年的4月2日設立為"世界自閉症關注日"。今年的孤獨星球-星光跑，正是為了在世界自閉症關注日前夕，通過運動和公益行動，讓更多人瞭解並接納自閉症群體。海納特教集團創始人郭潔波攜手同行"孤獨星球-星光跑"，用愛點亮星光本次星光跑活動，社會各界愛心人士和企業積極回應，踴躍報名參與並提供支持。活動將在3月30日早上7:30進行簽到和物資領取，並於8:30正式開跑。參與者將通過奔跑與陪伴，讓自閉症兒童及其家庭感受到社會的溫暖與關懷。"我們希望不僅僅是為孤獨症兒童提供康復和教育服務，更要讓社會認識到，他們的成長和發展需要社會各界共同努力。"郭潔波先生補充道，"同時，我們也希望吸引更多投資者關注特殊兒童教育產業，這不僅具有重要的社會價值，也蘊藏著可持續發展的經濟潛力。"未來，海納特教集團將持續深化在孤獨症康復教育領域的探索，為更多特殊兒童及其家庭帶去希望與改變。關於中國自閉症兒童康復事業的可持續發展近年來，中國自閉症兒童康復和教育行業逐步發展，社會關注度不斷提升。然而，行業仍面臨專業人才短缺、服務資源分佈不均、長期資金支持不足等挑戰。根據《中國自閉症教育康復行業發展狀況報告》，我國孤獨症群體已超過1000萬人，其中兒童超過200萬。海納特教集團創始人郭潔波先生表示："特殊兒童教育不僅是一項公益事業，更是具備長期可持續發展的社會產業。隨著社會認知的提升和政府政策的支持，行業正在從單一的康復培訓模式向'康復+教育+就業'的多元化方向發展，為投資者提供了可觀的經濟回報。"他進一步指出："當前，社會資本的進入將加速行業的標準化和規模化，提升服務品質，同時推動技術創新，如智慧輔助康復設備、AI特教平臺等，使更多孤獨症兒童獲得更高效的成長支持。這不僅有助於解決社會問題，也能帶來穩定的長期收益。"未來，隨著政府、社會組織及市場資本的共同推動，中國自閉症康復與教育行業將迎來更廣闊的發展前景，實現經濟效益與社會效益的雙贏。構建自閉症兒童全生涯支持體系海納特教集團創始人郭潔波先生表示："孤獨症兒童被稱為'星星的孩子'，他們的成長離不開社會的支持。海納希望通過此次星光跑活動，讓社會各界更加關注這一特殊群體，促進自閉症人士的社會融合。"為了幫助孤獨症群體實現更好的發展，海納於2019年創辦了"海納星智夢工廠"，整合特教康復、職業培訓與就業支持，探索"康復教育+職前培訓+就業支持"的發展模式。在龍華區民政局的支持下，海納還註冊成立了深圳市龍華區海納兒童康復中心，為孤獨症兒童提供從學齡期到職前技能培訓、再到就業支援的全鏈條服務，助力他們更好地融入社會。關於海納特教集團海納特教集團成立於2009年，致力於為心智障礙者提供涵蓋早期干預、融合教育、職業培訓、支持性就業等在內的全生涯服務。截至目前，海納已為5000多名心智障礙人士提供支援，在深圳乃至整個大灣區享有良好聲譽。自2009年成立以來，海納不斷拓展服務體系，包括發育評估、早期康復、融合教育、職業技能培訓、支持性就業等，幫助孤獨症群體更好地融入社會，提升生活品質。瞭解更多，請關注http://hainatejiao.com/媒體聯絡品牌：深圳海納特教集團聯繫：媒體團隊電話：(+86)18025411773網站：http://hainatejiao.com/ Copyright 2025 亞太商訊 via SeaPRwire.com.

- HuaTangNing completed its first full year for reimbursement under the National Reimbursement Drug List (NRDL), with continued expansion in hospital coverage. Compared with the 2023 year, sales volume increased by approximately 740%.- Sales revenue increased by 234% compared with the 2023 year, with cash reserves exceeding RMB 1 billion to fully support future R&D and commercialization activities.- A Phase I clinical study of our second-generation GKA, a once daily oral therapy, successfully completed in the United States. Our dorzagliatin-metformin fixed-dose combination formulation progressed smoothly and our product pipeline continued to advance and expand.- The Mendelian Randomization studies of human genetic data provided scientific evidence to support the exploration of glucokinase activation in diabetic complications and new clinical indications.- Manufacturing capacity of dorzagliatin continued to expand to meet growing market demand.- The establishment of Hua Medicine’s pharmaceutical sales and marketing team resulted in significant sales growth in the first two months of 2025, opening a new model of innovative drug commercialization.SHANGHAI, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (“the Company”, Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the “Reporting Period”), along with the Company’s business progress in 2024 and future business outlook. Hua Medicine has made significant strides in the commercialization of its core product, the glucokinase activator (GKA) dorzagliatin (trade name: HuaTangNing, as well as in R&D innovation and manufacturing capacity optimization, laying a solid foundation for the Company’s long-term sustainable development.Dr. Li Chen, Founder and the Chief Executive Officer of Hua Medicine, stated: “In 2024, HuaTangNing’s market performance was very encouraging. Its inclusion in the NRDL greatly enhanced the accessibility and affordability of this innovative drug, enabling more diabetes patients to benefit. In 2025, Hua Medicine established a pharmaceutical sales and marketing team, and HuaTangNing demonstrated strong growth momentum at the start of the year. With further market expansion and increasing patient awareness, we are confident in HuaTangNing’s market growth.”“Looking ahead, the Company will continue to explore HuaTangNing’s potential in personalized diabetes treatment and diabetes complications globally. By integrating big data and artificial intelligence technologies, we aim to expand our disease areas into immune homeostasis and neural homeostasis. We are confident with the close collaboration of Hua Medicine and its partners across the pharmaceutical R&D, production, and distribution chain, we can enable more patients to access and benefit from Chinese medicines, accelerating progress in realizing our vision ‘China leading pharmaceutical innovation to advance human health.’”Summary of Clinical Research and Operational Progress- Significant Revenue Growth, Strong Market Performance of HuaTangNing, and Positive Patient Feedback- 2024 marked the first full year for which our HuaTangNing was reimbursed under the National Reimbursement Drug List (“NRDL”) in China. Sales revenue increased by 234% to RMB255.9 million for the fiscal year 2024 compared with the same period in 2023. During the fiscal year 2024, HuaTangNing was sold in approximately 2,700 hospitals across China. As of December 31, 2024, Hua Medicine maintained a strong balance sheet with a cash balance of RMB1,139.8 million to support its full-scale commercialization, business development and R&D functions.- Since the launch of HuaTangNing in the fourth quarter of 2022, our pharmacovigilance team has been diligently monitoring the safety of dorzagliatin in the China market, and was recently recognized by the National Adverse Drug Reaction Monitoring Center as a national example for the pharmaceutical industry. As of December 31, 2024, Hua Medicine had monitored approximately 150,000 patients who have been prescribed HuaTangNing, and dorzagliatin has been observed to be safe and well tolerated by patients.- Effective January 1, 2025, Hua Medicine assumed full responsibility for the commercialization of HuaTangNing in China from its former sales and marketing partner, Bayer Healthcare Company Limited (“Bayer”). We recruited Mr. Lu Yu, a seasoned pharmaceutical sales executive with over 20 years of diabetes commercialization experience in China, to lead our sales and marketing efforts.- For the two months ended February 28, 2025, Hua Medicine sold approximately 592,000 packs of HuaTangNing, representing approximately RMB73.2 million in net sales. During the same period in 2024, approximately 202,000 packs of HuaTangNing were sold, representing approximately RMB24.5 million in net sales, The difference represents a significant increase in sales over a period during which the price per pack remained the same. This demonstrates a smooth transition of HuaTangNing’s commercialization in China from Bayer to Hua Medicine, with reinvigorated growth momentum.- Upon the termination of the Exclusive Promotion Service Agreement, the unamortized contact liabilities amounting to RMB1,243,499,000 were released to profit or loss, and will be recognized as a gain in 2025 by the Group. Both parties have confirmed in a signed letter that there are no outstanding matters arising from such termination, nor does either party owe the other party any obligation or liabilities from such separation.- Steady Progress in R&D Innovation, Continuously Enriching Product Pipeline- Hua Medicine made significant headway in preparing the future expansion of our glucokinase-targeted, glucose homeostasis-centered therapy into the international markets, specifically the United States. We successfully completed and announced the results of its single-ascending dose (“SAD”) study in the United States of our second generation GKA (HM-002-1005), in which we validated the feasibility of dorzagliatin as a once daily oral therapy for Type 2 diabetes (“T2D”) patients. We are currently developing the clinical dosage form for advancement of HM-002-1005 in a clinical proof-of-mechanism study.- Hua Medicine also made significant progress in developing fixed-dose combination formulations. The Company has been advancing its dorzagliatin-metformin fixed-dose combination product candidate into commercial dosage development, with process validation expected to be completed in 2025.- Based on human genetic data collected from studies of patients administered with dorzagliatin, the Mendelian Randomization methodology has been applied to predict the beneficial effects of dorzagliatin on related and significant diabetes complications, such as reduction in heart failure, coronary artery disease, memory loss and dyslipidemia. In addition, a separate Mendelian Randomization study provided genetic evidence supporting the causal effects of glucokinase activation on lowering the risk of frailty. These findings suggest that glucokinase activators may aid in the management of frailty and sarcopaenia in people with diabetes. We will continue our research and development efforts to explore new indications.- Through our SENSITIZE 3 clinical study in Hong Kong, Hua Medicine is advancing the potential of dorzagliatin in prediabetes, early treatment and prevention of Type 2 diabetes. In contrast with the approved 75mg dosage form of HuaTangNing, the Company is testing new 25mg and 50mg dosage formulations to explore these potential new indications. The Company is also supporting an investigator-sponsored trial in testing dorzagliatin’s efficacy in treating MODY-2 patients who suffered from genetic mutations that de-activated glucokinase. Early studies in humans by renowned diabetes experts Dr. Juliana Chan and Dr. Linong Ji have indicated the benefit of dorzagliatin in MODY-2 patients by improving their β-cell functions and glycemic control.- Hua Medicine is also advancing the combination of dorzagliatin with GLP-1RA, DPP-IV inhibitors and SGLT-2 inhibitor through combined effects in collecting real-world evidence and proof-of-concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indication into other diseases in metabolic disorders, such as obesity and MASH. - Hua Medicine will continue our engagement in diabetes prevention, opportunities in longevity and prevention of memory loss and eventually find a new way to increase healthy life span and longevity in humans.- Continued Expansion of Manufacturing Capacity, Plans to Launch Dorzagliatin in New Markets- Hua Medicine continues to invest in expanding its manufacturing capacity to meet anticipated market needs in 2026 and 2027.- Hua Medicine is also finalizing and preparing to submit registration applications for dorzagliatin to launch commercialization in the Macau and Hong Kong markets. We plan to submit both applications in 2025.- Hua Medicine continues to strengthen its intellectual property protection globally. As of December 31, 2024, the Company owned more than 200 granted patents covering its proprietary technology worldwide.Business outlook- There is a great opportunity for dorzagliatin and our 2nd generation GKA in China and the global oral anti-diabetes market. - We will strengthen our own commercialization efforts through hub and spoke development with focus on building up a strong internal sales and medical marketing organization to drive business growth in 2025. This will allow us to rebuild our strong connections directly to the medical community and better promote HuaTangNing in China and surrounding areas.- We continue to invest into digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.- We are working on the registration of dorzagliatin in HK and Macau region and engage partnerships in Southeastern Asia and Belt and Road nations. In addition, business development work on our 2nd generation GKA in regions with high incidences of obesity will be continued based on the initial success of the SAD study in the United States.Financial SummaryFor the year ended December 31, 2024:- Bank balances and cash position was approximately RMB1,139.8 million.- Total revenue was approximately RMB255.9 million, an increase of approximately 234% compared to the full year of 2023; approximately 2,105,000 packs of HuaTangNing were sold, an increase of approximately 740% compared to the full year of 2023.- Total other income was approximately RMB116.8 million, including approximately RMB95.7 million from the amortization of Bayer milestone income.- Total expenditures for the year was approximately RMB493.6 million, of which R&D expenses accounted for approximately RMB215.1 million.- Loss before tax was approximately RMB250.1 million, which was mainly attributable to the increase of selling expense and research and development expense.Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing(dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more information Hua MedicineWebsite:www.huamedicine.comInvestorsEmail:ir@huamedicine.comMediaEmail:pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2024 (the “Year” or “FY2024”).Financial Highlights- Contracts-in-hand remained at a high level of HK$11,052.7 million- Revenue rose to HK$6,450.1 million, up 5.2% year-on-year- Adjusted profit attributable to owners of the company recorded HK$206.0 million 1 with a growth of 10.2% 2 year-on-year, excluding a one-off expense and provision- Total dividend for the year amounted to HK4.38 cents per shareChairman Dr Mak Kin Wah said, “Capturing opportunities from shifting market priorities towards intelligent and digital solutions, data centres, environmental engineering and climate solutions, hospitals, infrastructure, and housing, we maintained a high level of contracts-in-hand across the Group’s diverse scope of business, providing a strong underlying foundation for the business over the next two years and beyond; this was notwithstanding the challenges around the world and in Hong Kong during the year.ATAL Tower, our new headquarters, is a significant investment that demonstrates our confidence in the future and our commitment to Hong Kong. We will continue to leverage our expertise and strong financial position to take up additional opportunities in the Hong Kong market, and explore further business development in overseas markets. Our investment in research and development, and innovation will enhance our core strengths and competitiveness. We will tirelessly live up to our motto of ‘We Commit. We Perform. We Deliver.’, ultimately driving our sustainable growth, optimising value for shareholders and other stakeholders, and contributing to the wider community.”Business Review: Building Services- This segment is the largest revenue contributor, with revenue up 5.3% to HK$3,933 million.- The recurring maintenance revenue increased by 40.2% to HK$422 million.- Leadership in the innovative construction technology of Multi-trade Integrated Mechanical, Electrical and Plumbing (“MiMEP”) received a major boost during the year, not only with the award of significant contract for a Grade A office building in Causeway Bay with the highest level of MiMEP application at 85% for a commercial building, but also with the development of our own systematic MiMEP methodologies and solutions.- The “MiMEP Design and Manufacturing Centre” and “MiMEP High Productivity Research Centre” in Zhuhai, as well as other MiMEP manufacturing facilities in Hong Kong, were established to integrate our capabilities in the Greater Bay Area with cutting-edge technology from Hong Kong.Environmental Engineering- The order intake significantly increased by 107.4% to HK$1,514 million, with contracts won for environmental infrastructure needed to enhance climate resilience, environmental protection, sustainability of water supply and waste treatment, and support for public housing and utilities.- The segment actively extended its expert services around the world, including Teresa in the Philippines, Dubai and other parts of the world.Information, Communications and Building Technologies (“ICBT”)- The order intake increased 22.5% to HK$757 million, with contracts-in-hand up 13.8% to HK$959 million.- The segment actively collaborated with leading manufacturers worldwide and in Mainland China to expand its technology reach and deliver cutting-edge solutions in diverse sectors.Lifts and Escalators- There was a significant growth in order intake and revenue, up 48.5% to HK$548 million and up 39.9% to HK$529 million respectively.- The two recently acquired lift companies in the United Kingdom (“UK”) contributed to revenue growth and made progress in the UK business.- The associate in the United States turned from a loss to a profit in FY2024 and made progress in expanding its business into additional cities in the South.For further details of the 2024 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.Remark:1. Profit attributable to the owners of the Company was HK$135.3 million, including a one-off expense of approximately HK$23.1 million before tax for relocation to the new consolidated headquarters to realise enhanced efficiency and synergy across business units, and a provision for expected credit loss of HK$88.0 million before tax to reflect risks with the recoverability of certain receivables and contract assets held by the Group in relation to certain construction companies.2. When compared with the adjusted profit attributable to owners of the company of HK$186.9 million in FY2023, which excludes a one-off dilution gain before tax upon completion of a private placement by an associate in Mainland China, a gain on disposal of interest before tax in an associate, and a provision before tax in respect of certain contracts in the healthcare sector.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in Macau, Mainland China, the United States and the United Kingdom. Serving a wide spectrum of customers from public and private sectors, the Group provides multi-disciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells Anlev lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 光大永年有限公司，為中國光大集團旗下物業租賃、物業管理及銷售持作出售物業公司（「光大永年」或「集團」，香港聯交所股份代號：3699）今天公佈截至2024年12月31日止年度（「回顧年度」）之全年業績。回顧年度，本集團的收益約為人民幣45.9百萬元（2023年：約人民幣46.8百萬元），較去年減少約1.9%，主要由於租金收入下跌所致。本公司權益股東應佔溢利約為人民幣25.3百萬元（2023年：約人民幣19.3百萬元），較去年增加約31.1%。溢利增加主要由於年內外匯（主要包括以人民幣以外貨幣計值的銀行存款）收益。每股基本盈利約為人民幣0.06元（2023年：人民幣0.04元）。董事會建議就截至2024年12月31日止年度派付末期股息每股人民幣1.05分（相當於1.14港仙）（2023年：人民幣0.60分），並派發特別股息每股人民幣0.34分（相當於0.37港仙）（2023年：無）。連同中期股息每股人民幣0.78分，全年股息為每股人民幣2.17分（2023年：每股人民幣1.66分）。於2024年12月31日，本集團的流動資產約為人民幣239.9百萬元（2023年： 約人民幣231.4百萬元）。流動資產增加主要由於年內現金及銀行結餘上升所致。本集團的流動負債為人民幣19.9百萬元（2023年： 約人民幣25.8百萬元）。流動負債減少主要是由於年內預收租金減少所致。物業租賃截至2024年12月31日止年度，本集團物業租賃業務的租金收入約為人民幣30.5百萬元（2023年：人民幣33.2百萬元）。由於每平方米（「平方米」）的平均租金下跌及向租戶提供租金補助，故總租金收入減少。本集團的租賃物業位於中國四川省成都市及雲南省昆明市。於2024年12月31日，本集團的物業組合包括三棟商業樓宇，即光大金融中心、光大國際大廈的部分物業及明昌大廈的部分物業，總建築面積（「總建築面積」）約為89,507平方米。物業管理服務本集團為其物業（即光大金融中心及光大國際大廈）提供物業管理服務。截至2024年12月31日止年度，本集團物業管理服務的收益約為人民幣15.4百萬元（2023年： 人民幣13.5百萬元）。年內，物業管理服務收益增加是由於餐廳收入的增加。於2024年12月31日，本集團管理的總建築面積為72,534平方米。投資物業本集團的投資物業主要包括擁有或按租賃權益持有以賺取租金收入及╱或資本增值的土地及╱或樓宇。於2024年12月31日，投資物業的公允價值為人民幣967.1百萬元（2023年：人民幣959.5百萬元），較去年增加約0.8%。截至2024年12月31日止年度，投資物業的估值收益約為人民幣6.6百萬元（2023年：約人民幣5.3百萬元）。展望回首2024年，全球經濟在經歷連續兩年放緩之後，正在回歸「正常」狀態，但增速仍然較為疲軟，增長動能減弱。然而，中國經濟在2024年上半年開局良好，儘管成長動力減弱，但經濟運行仍然相對平穩，經濟狀況持續回暖向好。隨著房地產市場投資放緩，新屋開工面積、房屋竣工面積以及新建商品房銷售面積持續放緩，物業管理行業規模增速因而受到影響。物業管理企業的發展戰略發生了重大轉變，企業未來在管理規模上的增長將不再是核心重點，而重心將逐步向服務品質和增值業務轉移。集團在過去一年商用物業受房地產市場波動影響程度相對較低，租戶及租務合同、出租率保持了相對穩定的態勢，使得集團在市場中保持了相對穩定的業績表現。展望未來，面對當前的經營環境，集團將繼續迎難而上，充分發揮與母公司中國光大集團的協同效應，借助「光大」品牌的知名度，發展多元化的增值服務。一方面，集團將致力於增加收入來源；另一方面，積極提升品牌影響力，把握行業調整期的機遇，進一步加強自身實力，鞏固競爭力及抗風險能力，力爭成為一家長期可持續發展且實力雄厚的企業。儘管2024年房地產及物業管理行業經歷了諸多挑戰，但在政策的支持與市場的逐步回暖下，集團對未來充滿信心，並將在穩健經營的基礎上，積極探索新的發展機遇，為本公司股東創造更大的價值。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 碧瑤綠色集團有限公司（「碧瑤」或「集團」；股份編號：01397.HK）欣然宣佈截至2024年12月31日止年度（「年內」）之全年業績。年內，集團收益為約26.0億港元，較去年增加約11.8%。集團年內純利約為56.5百萬港元，較2023年同比增加約17.3%。董事會建議派付本年度的末期股息每股3.8港仙。業務回顧及展望年內，清潔作為集團的核心業務，繼續於年內錄得增長，收益相比去年同期增加14.2%，至約2,086.8百萬港元，佔集團總收益約80.1%。集團為政府轄下的街道清潔服務版圖，覆蓋全香港共七區，服務人口約280萬，標誌碧瑤於香港清潔服務市場的領導地位。年內，集團的機動掃街車潔淨服務覆蓋香港各大區域。另外，集團亦為全港各大區的政府街市、設施及康樂場地提供清潔服務。此外，集團的其他清潔場地遍及各大醫院、政府診所、香港國際機場、學校、屋苑及私人機構等眾多不同場所，顯示集團的專業服務廣受認可。廢物管理及回收業務於年內收益錄得增長，相比去年同期增加約2.5%，至約285.8百萬港元，佔集團總收益約11.0%。廢物管理回收業務的毛利大幅增加約58.2%，至約33.5百萬港元，主要受惠於政府積極推動回收，大幅擴展包括廚餘的回收點網絡，便利市民參與並有效刺激收集量。集團繼續為政府轄下的五區提供廢物收集服務，服務人口約160萬。回收方面，集團作為環境保護署（「環保署」）服務承辦商，為香港數千個回收點提供收集服務（包括塑膠、玻璃樽、金屬、廢紙及廚餘），為市場領導者之一。集團於年內為公共場所及學校的回收箱，提供收集服務。碧瑤繼續為環保署的「塑膠回收先導計劃」服務合約，為香港區提供塑膠收集服務。此外，碧瑤亦為香港眾多環保署轄下的「綠在區區」回收環保站、回收便利點、智能回收機及不同機構，提供回收服務。另外，碧瑤為政府於香港多區負責玻璃容器收集及處理，以及廚餘收集，為市場領導者之一。綠色科技業務方面，集團積極發展綠色科技業務，通過結合智能數碼科技、大數據分析及物聯網技術，成功推出一站式智能回收系統。用戶通過實時數據準確掌握回收量，有助適時安排運輸、降低物流成本並減少碳排放。年內，集團贏得環保署兩份智能合約（分別提供智能廚餘回收機及智能磅），彰顯集團於綠色科技領域的產品創新、研發實力及市場領導地位，並支持香港邁向智慧城市的目標。現時集團綠色科技產品（如：智能回收機、智能廚餘回收機及智能磅等）於年內帶動集團的收入貢獻，已廣泛應用於政府機構、公營及私人住宅、商場、大學、醫院、大型展覽場館等，為市民提供便捷的回收體驗，提升回收效率，推動香港可持續發展進程。集團與怡和機器有限公司合作位於香港屯門環保園的生物炭工廠已於年內試營運，通過熱解技術將園林廢料轉化為高質量生物炭以作各種應用，從而達到「轉廢為材」的目的。園藝服務業務方面，集團客戶涵蓋大型私人住宅、政府處所、學校、商場、酒店、機場、香港房屋委員會、香港賽馬會、香港科學園、香港大學、香港科技大學及嶺南大學等各個類型。年內新中標的合約包括港深創新及科技園、油旺微型公園及東涌西新發展區。蟲害管理方面，集團年內繼續為黃大仙區及大埔區提供蟲害管理服務。此外，集團分別為古物古蹟辦事處轄下29個古蹟及華人廟宇委員會轄下24間廟宇，提供白蟻防治及監測服務。截至2024年12月31日，集團的手頭合約約38.9億港元，為日後年度，迎來可觀的收益。隨著以「市場主導模式」的塑膠飲料容器及紙包飲品盒生產者責任計劃有序實行，集團認為措施提供經濟誘因鼓勵市民積極參與回收，預計刺激塑膠飲料容器、紙包飲品盒回收率，促進回收行業健康發展，協助香港構建循環經濟及綠色產業。此外，集團於本財政年後贏得食物環境衞生署（「食環署」）供應太陽能智能廢物收集箱的服務合約。根據政府資料，食環署計劃於2026年底前在約300個地點增設多種廢物收集設施，包括太陽能廢物壓縮箱，進一步優化鄉郊地區廢物收集及改善環境衞生。集團的產品以可持續發展及智慧科技為設計理念，專為香港不同場景而研發，旨在提升收集質量、支持智慧城市建設、塑造宜居環境。隨著香港聯合交易所有限公司要求上市公司加強氣候相關揭露，相信市場對集團有關ESG的業務將與日俱增。展望未來，集團將在鞏固核心業務市場份額的同時，加快在香港及國際市場的擴展步伐，並適時探索併購、合營及新業務機會，推動業務增長，為股東創造長遠價值。有關集團2024年度業績公告詳情，請瀏覽以下網址：https://www.baguio.com.hk/zh-hant/investor/notices/碧瑤綠色集團簡介：碧瑤綠色集團（股份編號：01397.HK）成立於 1980 年，為香港最大的綜合環境管理方案供應商之一，提供環衞保潔、資源回收、循環再造、廢物管理、綠色科技、綠色產品、園藝綠化工程及害蟲防治等。集團應用最新科技，提供創新環境解決方案，為不同領域的客戶提供服務，包括政府部門、各大機構及跨國企業。集團努力不懈地提升環境、社會及管治(ESG)的表現，以推進集團的可持續發展，為了更綠的明天，實現將香港推動成為更清潔、更綠色、更健康城市的願景。如有垂詢，請聯絡：碧瑤綠色集團有限公司 投資者關係部電話: (852)2541 3388 電郵: ir@baguio.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 周大福人壽宣佈，其碳減排目標已正式通過「科學基礎減量目標倡議」（Science Based Target initiative或SBTi）認證，這一成果彰顯了周大福人壽對碳減排的決心，並為公司持份者提供了一套可衡量的標準，以監測公司在這方面的持續努力。去年十月，周大福人壽制定與《巴黎協定》一致的科學基礎目標，並成為首家主要在大灣區營運的「銀行、多元化金融、保險業」界別的機構向SBTi提交碳減排承諾書，牽頭推動可持續發展。SBTi是一個全球性的企業氣候行動組織，旨在協助企業在應對氣候危機方面發揮應有作用。周大福人壽的目標是在2029財年，將範圍1和範圍2的溫室氣體排放量減少37.8%（以2023財年水平為基準）。此外，就範圍3的投資組合目標，周大福人壽承諾到2029財年：- 將其上市股票和公司債券投資組合中的電力行業的每兆瓦時溫室氣體排放量減少59%（以2023財年水平為基準），- 在其上市股票和公司債券投資組合中，將至少44.8%（以投資價值計算）投資於已制定SBTi認證目標的公司。以上兩項舉措將涵蓋其總投資和貸款資產的65%。周大福人壽執行董事兼行政總裁葉文傑表示：「周大福人壽深明氣候行動不僅是一項重大責任，更有助於推動意義深遠的變革。我們一直與周大福創建緊密合作，以確保一致實現2050年淨零排放目標。此次碳減排目標獲得認證，充分體現了我們在減少營運和投資組合排放量的堅定決心。這一里程碑再次證明了我們致力於建設可持續未來，同時為持份者開創保險新價值。」周大福人壽將透過以下策略和行動，實現其碳減排目標：範圍1和範圍2營運碳減排措施：- 電動車轉型：將現有的租賃或自有車隊替換為電動車。- 提升能源效率：探索提高公司各辦公室的能源效率的機會。- 購買可再生能源證書：在優先推動電動車轉型和提升能源效率的同時，周大福人壽亦將研究從本地能源供應商購買可再生能源或可再生能源證書，或為同一市場內沒有其他選項的前提下，從亞洲及其他海外市場購買國際可再生能源證書，以進一步減少範圍2的剩餘營運排放。降低範圍3中15個類別排放的措施：- 積極擁有權（Active Ownership）與參與策略：分階段實施參與策略，以促進實際減排。- 氣候融資：探索與環境、社會及企業管治（ESG）相關的產品及氣候融資機會。- 策略與治理：建立完善的管治架構，以推動氣候行動。- 政策與倡導：尋求機會建立合作與夥伴關係，以擴大影響力。周大福人壽選擇上述碳減排措施，是因為這些措施預計將對公司的氣候轉型產生最直接的影響。截至2024 年6 月，公司投資組合的碳足跡已較2023年同期的基數減少了超過15%。此外，公司已投資超過35 億港元於獲ESG 標籤的債券及減碳基金，主要聚焦亞洲市場，以支持區內綠色經濟轉型。關於周大福人壽保險有限公司周大福人壽保險有限公司（「周大福人壽」）扎根香港40年，為周大福創建有限公司（「周大福創建」）（香港股份代號：659）的全資附屬公司，也是香港最具規模的壽險公司之一。作為周大福企業成員，周大福人壽緊扣鄭氏家族（「周大福集團」或「集團」）多元業務體系的雄厚資源，致力為客戶及其摯愛家人於「生活、成長、健康、傳承」的人生旅程中，提供個人化的匠心規劃、終身保障及優質體驗。憑藉集團財務實力及環球投資佈局，周大福人壽矢志成為亞太區領先的保險公司，持續開創保險新價值。傳媒聯絡周大福人壽保險有限公司品牌發展及傳訊部陳佳容+852 2591 8504deronie.tan@ctflife.com.hk 周大福人壽保險有限公司（於百慕達註冊成立之有限公司） Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 3月26日，中創新航科技集團股份有限公司（「中創新航」或「公司」，股票代碼：3931.HK）公佈截至2024年12月31日止年度（「報告期」）經審核綜合全年業績。2024年，中創新航規模效應全面釋放，經營業績取得穩健增長。報告期內，公司收入由截至2023年12月31日止年度的人民幣27,005.89百萬元增長至截至2024年12月31日止年度的人民幣27,751.53百萬元，增長2.8%；利潤由截至2023年12月31日止年度的人民幣437.16百萬元增長至截至2024年12月31日止年度的人民幣843.63百萬元，增長93.0%。公司每股基本盈利由截至2023年12月31日止年度的人民幣0.1661元增長至截至2024年12月31日止年度的人民幣0.3336元，增長100.8%。作為國際新能源領軍企業，公司在報告期內於各市場領域全面發力，實現持續高速發展。其中，根據SNE Research最新統計，公司2024年度動力電池裝車量排名全球第四、國內第三。根據InfoLink數據，公司2024年度儲能電芯出貨量排名全球第五。2024年，公司縱深推進國內乘用車市場合作，裝機量穩步提升。報告期內，公司配套車型新增25款，累計裝車超過200萬台，交付量超100GWh。在純電領域，公司成功助力小鵬、吉利、長安、廣汽等多家頭部客戶主銷車型的升級迭代與量產配套，實現多款合資品牌全新車型的量產交付，推進立體化市場體系的構建；在混動領域，公司在加速推進與吉利、零跑新混動項目合作的同時，成功實現奇瑞、東風、北汽等多家頭部客戶多款混動車型的量產配套，裝機量在報告期內實現高速增長，同比增長近200%。另外，在國際市場上，公司加速全球化市場佈局，於報告期內獲得豐田、馬自達、福特、大眾、奧迪等國際品牌定點，持續擴大歐洲及東南亞市場客戶基數，交付數量穩步攀升，交付產品類型日益豐富，海外裝機量同比增長105%，再創新高。此外，在商用車市場，公司年度新車公告同比增長150%，國內裝機量較上年同期增長85.2%，目前已實現市場主流產品全覆蓋、場景全賦能，並已與奇瑞、吉利、瑞馳、福田、東風、長安、金龍等頭部客戶深入合作，全面配套交付行業主流車型。在儲能市場，公司單月儲能電芯出貨突破5GWh，實現出貨量持續大幅增長，314Ah電芯產品在行業內率先實現大規模批量穩定交付，獲得戰略客戶對產品及交付能力的高度認可。報告期內，公司在國際市場實現重大突破，包括完成多個國際頭部儲能業主、EPC、集成商供貨商準入，進入客戶白名單並實現批量交付。並且作為高性能儲能電芯的供應商，公司成功獲得全球最大儲能項目全部7.8GWh訂單並實現交付，並成功實現首個自投電站項目落地。與此同時，公司在船舶市場成果同樣顯著，包括獲得全球最大石油公司首個電動船項目，斬獲首個「兆瓦級」船用電池系統國際訂單，「海洋工程船」領域實現「零突破」，新加坡港口電動船舶實現批量訂單轉化，以及成功進入美國高端遊艇市場。公司以創新引領快速發展，始終堅持產品與技術領先戰略，面向未來進行研發佈局，從材料創新、結構創新、製造創新、系統創新等多維度推動電池技術的不斷進步，多項技術與產品做到了全球領先，全場景打造硬核產品力，引領行業發展新高度。2024年，公司成功發佈「頂流」、「至遠」、「至久」、「無界」系列新品，在高比能、高安全、長壽命、超快充和全氣候等產品性能方面全方位創新超越，為市場和客戶提供最具價值貢獻的全場景產品解決方案。同時，結合自身技術能力和產業化實力，不斷追求動力電池的高能量密度和穩定的安全性能，公司在報告期內推出更具競爭力的三元系、磷酸鹽系新產品，持續深耕電力儲能（新能源發電側、電網側）、工商業儲能、戶用儲能等應用場景，持續保持產品力領先。關於中創新航集團有限公司中創新航（3931.HK）是專業從事鋰電池、電池管理系統及相關集成產品和鋰電池材料的研製、製造、銷售和市場應用開發的新能源高科技企業。作為電池專家，公司致力於構建全方位能源運營體系，為以動力及儲能為代表的新能源全場景應用市場提供完善的產品解決方案和全生命周期管理。目前，公司已建立江蘇、福建、四川、湖北、安徽、廣東等多個產業基地，完成全方位國內產業佈局，同時已設立歐洲產業基地、泰國產業基地，大力拓展海外產業佈局，打造擁有規模化智能製造實力的國際化領先企業。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Baguio Green Group Limited ('Baguio' or the 'Group', Stock Code: 01397.HK) is pleased to announce its annual results for the year ended 31 December 2024 (the 'Year').Revenue for the Year amounted to approximately HK$2.60 billion, representing an increase of approximately 11.8% as compared to the same period last year. Profit for the Year amounted to approximately HK$56.5 million, representing an increase of approximately 17.3% as compared to the same period last year. The Board recommends the payment of a final dividend for the Year at HK$3.8 cents per share.Business Overview and ProspectsThe Group’s core business, cleaning services, recorded growth in the Year. Revenue from cleaning services increased by 14.2% to approximately HK$2,086.8 million, accounting for approximately 80.1% of the Group’s total revenue. The Group’s Government-related street cleaning services cover a total of seven districts, serving a population of approximately 2.8 million, marking Baguio’s leading position in the Hong Kong cleaning services market. During the Year, the Group’s mechanical street sweeping services covered various districts in Hong Kong. In addition, the Group provides cleaning services for Government markets, facilities, and leisure venues across various districts in Hong Kong. The Group’s other cleaning sites cover hospitals, Government clinics, Hong Kong International Airport, schools, housing estates and private institutions, demonstrating that the Group’s professional services are widely recognised.Waste management and recycling business recorded growth in revenue during the Year which increased by approximately 2.5% to approximately HK$285.8 million, accounting for approximately 11.0% of the Group’s total revenue. Gross profit of the waste management and recycling business increased significantly by approximately 58.2% to approximately HK$33.5 million, mainly due to the Government’s proactive promotion of recycling and the substantial expansion of the network of recycling spots, including those for food waste, which facilitated public participation and effectively stimulated collection. The Group continued to provide Government-related waste collection services to five districts, serving a population of approximately 1.6 million. In terms of recycling, the Group is contracted by the Environmental Protection Department (“EPD”) to provide collection services for thousands of recycling spots (including plastic, glass bottles, metals, waste paper and food waste) across Hong Kong, and is one of the market leaders. During the Year, the Group provided collection services for recycling bins in public places and schools. Baguio continued to provide plastic collection services for several districts under the EPD Plastic Recycling Pilot Scheme contract. Baguio also provides collection services for Recycling Stations of“GREEN@COMMUNITY”, introduced by the EPD, recycling convenience spots and smart recycling machines, and other institutions in Hong Kong. In addition, the Group also provides the Government with glass bottles collection and management services and food waste collection services in several districts in Hong Kong, and is one of the market leaders.Regarding green technology business, the Group has proactively developed its green technology business and successfully launched a one-stop smart recycling system by integrating smart digital technologies, big data analysis and Internet of Things technologies. Users can accurately understand the amount of recycling through real-time data, which helps to schedule timely transportation and reduce logistics costs and carbon emissions. During the Year, the Group won two smart contracts from the EPD (in relation to provision of smart food waste recycling machines and smart balances, respectively), demonstrating the Group’s outstanding capabilities in product innovation, research and development, and leading market position in the green technology sector as well as its alignment with Hong Kong’s goal of becoming a smart city. The Group’s existing green technology products including smart recycling machines, smart food waste recycling machines, and smart balances contributed to the Group’s revenue during the Year, and are widely used in Government organizations, public housing and private residential estates, shopping malls, universities, hospitals, large-scale exhibition centers, etc. It not only provides convenient recycling experience to the public but also improve the recycling efficiency, thus supporting the sustainable development of Hong Kong.In partnership with Jardine Engineering Corporation Limited, the Pilot Biochar Production Plant at the EcoPark in Tuen Mun was commenced trial operation during the Year. By converting yard waste into high-quality biochar with pyrolysis technology for various applications, the production plant effectively “turns waste into useful resources”.The Group provides landscaping services for a wide range of clients, including large private residences, Government premises, schools, shopping malls, hotels, airports, Hong Kong Housing Authority, Hong Kong Jockey Club, Hong Kong Science Park, the University of Hong Kong, Hong Kong University of Science and Technology and Lingnan University, etc. The newly awarded contracts won by the Group during the Year coversHong Kong-Shenzhen Innovation and Technology Park, microparks in Yau Ma Tei and Mong Kok, and the Tung Chung New Town Extension (West).For pest management business, the Group continued to provide pest management services in Wong Tai Sin and Tai Po districts during the Year. In addition, the Group provided termite control and monitoring services to 29 monuments under the Antiquities and Monuments Office and 24 temples under the Chinese Temples Committee respectively.As of 31 December 2024, the Group’s contracts on hand amounted to approximately HK$3.89 billion, providing considerable revenue for subsequent years.With the orderly implementation of the “market-led” approach in Producer Responsibility Scheme on Plastic Beverage Containers and Beverage Cartons, the Group considers that the measure provides economic incentives to encourage citizens to proactively participate in recycling, which is expected to stimulate the recycling rate of plastic beverage containers and cartons, promote the healthy development of the recycling industry, and help build a circular economy and green industry in Hong Kong.In addition, the Group was awarded a service contract from the Food and Environmental Hygiene Department (“FEHD”) to supply solar-powered smart collection bins after the Year. According to the Government’s information, the FEHD plans to install a variety of waste collection facilities at around 300 locations by the end of 2026, including the solar-powered compacting refuse bins with an aim to further optimize waste collection in rural areas and improve environmental hygiene. The Group’s product is designed with a focus on sustainability and smart technology, tailored to meet the needs of different scenarios in Hong Kong, with the goal of enhancing waste collection quality, supporting smart city development, and creating a livable environment.As The Stock Exchange of Hong Kong Limited requires listed companies to enhance climate-related disclosure, it is believed that to drive an increasing demand for the Group’s ESG-related business.Looking forward, the Group will consolidate the market share of its core businesses and actively engage in expansions in Hong Kong and international markets and explore mergers and acquisitions, joint ventures and new business opportunities to drive business growth and create long-term value for the shareholders.For details of the Group's 2024 annual results announcement, please visit the following website:https://www.baguio.com.hk/en/investor/notices/About Baguio Green GroupEstablished in 1980, Baguio Green Group (Stock code: 01397.HK) is one of Hong Kong’s largest integrated environmental management solution providers. It provides a full spectrum of professional services including professional cleaning, waste collection & recycling, waste management, green technology, green products, horticulture & landscaping, and pest control. The Group delivers innovative environmental solutions using the latest technologies to serve a wide range of customers in various sectors including Government departments, statutory organizations and multinational corporations. Fully committed to ESG, the Group works relentlessly to advance sustainable development and create a cleaner, greener, healthier city for a greener tomorrow.For further information, please contact:Baguio Green Group LimitedInvestor Relations DepartmentTel: (852) 2541 3388Email: ir@baguio.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

Industry leaders converge to explore technology-driven strategies for enhancing customer experiencesBENGALURU, INDIA, Mar 26, 2025 - (ACN Newswire via SeaPRwire.com) - In a world where customer experience (CX) is increasingly defining business success, the Bengaluru edition of Team Marksmen Network's CX Transformation Conclave 2025 scheduled for 21st March, 2025 at Taj Vivanta, Bengaluru, proved to be a beacon of insight and innovation. Bringing together an array of industry stalwarts and forward-thinking leaders, the event delved into the transformative power of technology in shaping exceptional customer journeys, offering actionable strategies to future-proof businesses.As India continues to climb the global CX maturity ranks — standing third worldwide and leading the Asia-Pacific region, according to an industry report — the conclave highlighted the immense potential that lies in crafting thoughtful, technology-enabled customer experiences.However, despite 79% of Indian firms acknowledging CX as a revenue driver, only 17% have achieved the elusive goal of providing "exceptional" customer service. The event set out to bridge this gap, serving as a platform for industry experts to exchange ideas and chart a path toward customer-centric innovation.The day featured a series of engaging keynote addresses, panel discussions, and interactive sessions that covered diverse facets of CX transformation. Attendees gained insights into the power of omnichannel strategies, where the seamless integration of digital and physical touchpoints ensures continuity and consistency in every customer interaction. The role of emerging technologies such as artificial intelligence, machine learning, and predictive analytics was also explored, with experts showcasing how these innovations can unlock personalised, real-time experiences that resonate deeply with consumers.One of the key takeaways was the importance of balancing innovation with empathy. While technology offers endless possibilities for personalisation and efficiency, the human element remains crucial. Speakers emphasised that businesses must strive to forge genuine connections with customers, understanding their needs, emotions, and expectations to deliver experiences that are not just satisfying but truly memorable.Throughout the event, the importance of measuring and optimising CX investments was underscored. Experts shared frameworks for tracking the impact of CX initiatives on key metrics such as customer lifetime value, retention rates, and revenue growth, ensuring that businesses can continually refine their approaches for maximum impact.This industry-centric platform was brought to life by its industry partners, namely Presenting Partner NICE, AI Transformation Partner Exotel, and Associate Partner Ubona Technologies.The CX Transformation Conclave also saw a select cross-section of eminent organisations lauded for their trailblazing CX efforts. This included:Ather Energy LimitedBrick and Bolt - home and commercial constructionCashfree PaymentsElectrolux India Private LimitedFirstsourceFlipkartForce PointInfosys FinacleITC InfotechITC LimitedKapiva AyurvedaLTIMindtreePrestige GroupXiaomi Technology India Private LimitedReflecting on the event's impact, Rajesh Khubchandani, Co-Founder and MD, Team Marksmen Network, said, "The insights shared at the CX Transformation Conclave reaffirmed that customer experience is more than just a business strategy — it’s the heart of every successful organisation. Technology is an incredible enabler, but true transformation lies in embracing a customer-first mindset at every level. Our goal with this event was to bring together brilliant minds to explore the future of CX and empower businesses to harness innovation in creating meaningful, lasting connections with their customers."As the curtains closed on yet another successful edition of the CX Transformation Conclave, one thing was clear: the future of customer experience lies in a harmonious blend of technology, empathy, and continuous evolution. The insights shared and connections forged at the event are sure to inspire a new wave of customer-centric innovation, positioning businesses to thrive in the ever-evolving experience economy.About Team MarksmenThrough an array of bespoke industry-centric knowledge platforms, using a variety of formats, such as Roundtables, Summits & Conferences, Workshops, and Recognition Ceremonies, Team Marksmen helps senior industry decision makers navigate through issues of critical importance and informs their world-view for better decision-making.Team Marksmen has successfully executed more than 50 events that have featured 1500+ brands, helping businesses across industries create opportunities to engage audiences through on-ground and virtual experiences. The organisation empowers industry leaders by providing them with insights, ideas, and opportunities that fits their unique industry and context. Through content shared via its flagship website, Marksmen Daily, and print magazine ‘in Focus’ focused on business, leadership, and lifestyle, they help advance the practice of management. Meanwhile, through strategic initiatives like Marksmen Media, it helps organisations achieve their objectives through a plethora of bespoke digital and content strategies.To know more about this unique initiative, write to us at contact@teammarksmen.com. Copyright 2025 ACN Newswire via SeaPRwire.com.

DUBAI, UAE, Mar 25, 2025 - (ACN Newswire via SeaPRwire.com) - Vibe Marketing Tech Fest – the Middle East’s largest marketing technology summit, will take place on April 23 and 24, 2025, in Dubai, UAE.Digitalisation has revolutionised how customers engage with brands, transforming the traditional linear funnel into an intricate web of touchpoints. Today’s customer journey is dynamic, interconnected, and far from predictable.Marketers must now navigate a landscape where customer expectations are higher, attention spans are shorter, and engagement spans across multiple platforms and moments.The 16th global edition of Vibe Marketing Tech Fest (VMF) will delve into these challenges, offering insights, strategies, and Martech solutions that empower modern marketers to adapt, innovate, and thrive in this new reality.The theme will focus on the convergence of marketing technologies, ad technologies, and ad journeys and explore how marketers need to adapt, be dynamic, and incorporate customer-centricity into their approach.Marketers must leverage the power of real-time data and technology to comprehend where a customer changes trajectory and what influences their decisions in doing so. “Customers are discerning and any disruption in convenience can hamper the path to conversions. Brands must adapt to fragmented and dynamic paths to purchase, driven by real-time data and emerging AI capabilities. Vibe Marketing Tech Fest puts the spotlight on the consumer, and how brands can navigate the changing technology landscape to deliver this convenience. With this edition, we have added themes like app marketing, ad tech integration, growth, digital marketing and retail media networks,” said Sanjay Swamy, Director at Martechvibe.Top conversations at VMF 2025 will cover:Engagement, Apps & SocialAI, Automation & TechMartech, Adtech & DataBrand Growth & RetentionThe conversations at VMF tackle real-world challenges affecting marketers today, with a look at preparing for possible scenarios in the near future. Rajesh Verma, General Manager, Middle East, Epsilon said, “We need forward-facing platforms like these to help dispel the myths that surround marketing and tech in the Middle East. Take retail media as an example; many believe retail media strategies rely solely on online behaviour and demographics, overlooking the power of transactional data, or that retail media only occurs on a retailer’s website. These gatherings provide an opportunity to educate marketers on the true potential of new media opportunities, and how to avoid the pitfalls. They foster important connections that place attendees in a much better position to navigate the complexities of the evolving landscape.”Richard Shotton, Founder of Astroten, a behavioural science consultancy and author of The Choice Factory and The Illusion of Choice, will deliver the keynote on how human decision-making remains remarkably constant in an evolving technology landscape in his session titled The Enduring Power of Behavioural Science. “It’s increasingly common to see brands and agencies incorporate consumer psychology as part of their process, although it’s not often systematically applied. There’s still an over-reliance on intuition, or when research happens, it’s based on claimed data. For example, creative routes are tested by asking people which ads they think would make them purchase… It’s not that respondents deliberately mislead researchers, just that nobody is aware of all the elements that influence their decisions. When asked, people don’t — in fact, can’t — tell you what motivates them. So, findings from a lot of market research can never uncover the whole truth. There’s still more headroom to align research with genuine motivation through the application of behavioural science.”Speakers like Scott Brinker, Sir Martin Sorrell, Brian Solis, Neil Patel, Darell Alfonso, Fernando Machado, David Raab, Rob Bloom, and Steve Lok have delivered rich sessions in the previous editions of the summit.This year’s speakers include Alexis Jean Baptiste - Chief Data & Analytics Officer | L'Oréal, James Dutton – Chief Product Officer | UM MENAT, Mai Cheblak - Vice President Group Media & Social | Emirates NBD, Marwen Ben Messaoud - Head of Growth Middle East, Africa, South Asia | Spotify, Matthew Horobin - Associate Director Customer Experience | Modon Holdings, Mustafa Bohra - Associate Director - Martech and Analytics | Careem, Nandakumar Vijayan - Global Director, Marketing & Communications | LuLu Group International, Oleg Nesterenko - Chief Marketing Officer | Storytel, Charlotte Davis | Acting Director of Retail Media | Majid Al Futtaim, Sohail Nawaz MBE - Head of Retail Media | Landmark Group, Sevgi Gur - Chief Marketing Officer | Property Finder, Rishi Gupta - Regional Director: Middle East & Africa | Nothing, and many more.For more information, visit Vibe Marketing Tech Fest 2025.About VMFFounded in 2018, Vibe Marketing Tech Fest (VMF) is one of the world’s largest and most influential marketing tech conferences. It is the premier gathering for marketing, technology, product, CRM, revenue, and CX leaders. Designed to explore the latest trends, strategies, and cutting-edge tools shaping the marketing landscape, VMF serves as the ultimate platform where marketing pioneers connect with technology innovators.Join industry leaders as they network, exchange insights, and redefine the future of marketing through the power of technology.Media contact:Mrunalini Polmrunalini@vibeprojects.com Copyright 2025 ACN Newswire via SeaPRwire.com.